论文部分内容阅读
目的：研究多药耐药相关蛋白在非小细胞肺癌的表达情况及其两者关系。方法：应用单克隆抗体ＱＣＲＬ－１行ＬＳＡＢ免疫组化法研究６１例非小细胞肺癌组织中多药耐药相关蛋白表达水平。结果：肺癌组织中多药耐药相关蛋白表达的总阳性率为６８．９２％；癌旁正常肺组织呈阴性或弱阳性表达；高和中分化肺癌多药耐药相关蛋白表达的阳性率高于低分化癌（Ｐ＜０．００５）；Ⅰ－Ⅱ期肺癌多药耐药相关蛋白表达的阳性率高于Ⅲ－Ⅳ期者（Ｐ＜０．０１）。结论：表明多药耐药相关蛋白是非小细胞肺癌多药耐药的重要参与因素。
Objective: To study the expression of multidrug resistance-associated protein in non-small cell lung cancer and their relationship. METHODS: The expression of multidrug resistance-associated protein in 61 non-small cell lung cancer tissues was studied by immunohistochemistry using monoclonal antibody QCRL-1 and LSAB immunohistochemistry. Results: The total positive rate of multidrug resistance-associated protein expression in lung cancer tissue was 68.92%; the normal lung tissue was negative or weak positive expression in lung cancer; the positive rate of multidrug resistance-associated protein expression in high and moderately differentiated lung cancer was high The positive rate of multidrug resistance-associated protein expression in poorly differentiated carcinoma (P<0.005); stage I-II lung cancer was higher than that in stage III-IV (P<0.01). CONCLUSIONS: This suggests that multidrug resistance-associated protein is an important factor for multidrug resistance in non-small cell lung cancer.